vs

Side-by-side financial comparison of Keros Therapeutics, Inc. (KROS) and MICROVISION, INC. (MVIS). Click either name above to swap in a different company.

Keros Therapeutics, Inc. is the larger business by last-quarter revenue ($385.0K vs $223.0K, roughly 1.7× MICROVISION, INC.). On growth, MICROVISION, INC. posted the faster year-over-year revenue change (-86.5% vs -87.3%). Keros Therapeutics, Inc. produced more free cash flow last quarter ($106.0M vs $-59.4M). Over the past eight quarters, Keros Therapeutics, Inc.'s revenue compounded faster (593.7% CAGR vs -51.7%).

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for hematological disorders, musculoskeletal diseases and anemia, serving underserved patient groups with unmet medical needs from its core U.S. base.

MicroVision Inc. is a technology company specializing in advanced LiDAR sensors, miniature display solutions, and perception software. Its core products serve automotive ADAS, augmented reality devices, consumer electronics, and industrial automation markets, delivering high-precision, low-power sensing technologies for next-generation smart applications.

KROS vs MVIS — Head-to-Head

Bigger by revenue
KROS
KROS
1.7× larger
KROS
$385.0K
$223.0K
MVIS
Growing faster (revenue YoY)
MVIS
MVIS
+0.9% gap
MVIS
-86.5%
-87.3%
KROS
More free cash flow
KROS
KROS
$165.4M more FCF
KROS
$106.0M
$-59.4M
MVIS
Faster 2-yr revenue CAGR
KROS
KROS
Annualised
KROS
593.7%
-51.7%
MVIS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
KROS
KROS
MVIS
MVIS
Revenue
$385.0K
$223.0K
Net Profit
Gross Margin
Operating Margin
Net Margin
Revenue YoY
-87.3%
-86.5%
Net Profit YoY
49.0%
-21.2%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
KROS
KROS
MVIS
MVIS
Q4 25
$385.0K
$223.0K
Q3 25
$14.3M
$241.0K
Q2 25
$18.2M
$155.0K
Q1 25
$211.2M
$589.0K
Q4 24
$1.6M
Q3 24
$388.0K
$190.0K
Q2 24
$37.0K
$1.9M
Q1 24
$83.0K
$956.0K
Net Profit
KROS
KROS
MVIS
MVIS
Q4 25
Q3 25
$-7.3M
$-14.2M
Q2 25
$-30.7M
$-14.2M
Q1 25
$148.5M
$-28.8M
Q4 24
$-31.2M
Q3 24
$-53.0M
$-15.5M
Q2 24
$-45.3M
$-23.9M
Q1 24
$-43.1M
$-26.3M
Gross Margin
KROS
KROS
MVIS
MVIS
Q4 25
Q3 25
Q2 25
Q1 25
6.6%
Q4 24
-149.5%
Q3 24
Q2 24
18.2%
Q1 24
-33.6%
Operating Margin
KROS
KROS
MVIS
MVIS
Q4 25
Q3 25
-107.9%
-5278.4%
Q2 25
-219.2%
-9455.5%
Q1 25
72.0%
-2383.7%
Q4 24
-1119.5%
Q3 24
-15117.8%
-8266.3%
Q2 24
-136321.6%
-1296.4%
Q1 24
-58413.3%
-2793.9%
Net Margin
KROS
KROS
MVIS
MVIS
Q4 25
Q3 25
-51.0%
-5899.2%
Q2 25
-169.0%
-9180.0%
Q1 25
70.3%
-4886.1%
Q4 24
-1888.2%
Q3 24
-13648.5%
-8166.8%
Q2 24
-122316.2%
-1259.5%
Q1 24
-51944.6%
-2752.4%
EPS (diluted)
KROS
KROS
MVIS
MVIS
Q4 25
Q3 25
$-0.18
$-0.05
Q2 25
$-0.76
$-0.06
Q1 25
$3.62
$-0.12
Q4 24
$-0.15
Q3 24
$-1.41
$-0.07
Q2 24
$-1.25
$-0.11
Q1 24
$-1.21
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
KROS
KROS
MVIS
MVIS
Cash + ST InvestmentsLiquidity on hand
$287.4M
$74.9M
Total DebtLower is stronger
$19.2M
Stockholders' EquityBook value
$303.1M
$55.5M
Total Assets
$338.0M
$103.1M
Debt / EquityLower = less leverage
0.35×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
KROS
KROS
MVIS
MVIS
Q4 25
$287.4M
$74.9M
Q3 25
$693.5M
$99.5M
Q2 25
$690.2M
$91.4M
Q1 25
$720.5M
$69.0M
Q4 24
$74.7M
Q3 24
$530.7M
$43.2M
Q2 24
$405.9M
$56.6M
Q1 24
$442.4M
$73.1M
Total Debt
KROS
KROS
MVIS
MVIS
Q4 25
$19.2M
Q3 25
$29.0M
Q2 25
$32.3M
Q1 25
$30.1M
Q4 24
$33.0M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
KROS
KROS
MVIS
MVIS
Q4 25
$303.1M
$55.5M
Q3 25
$703.6M
$90.7M
Q2 25
$706.7M
$77.1M
Q1 25
$728.9M
$53.2M
Q4 24
$48.8M
Q3 24
$532.8M
$65.9M
Q2 24
$420.9M
$78.7M
Q1 24
$453.9M
$93.8M
Total Assets
KROS
KROS
MVIS
MVIS
Q4 25
$338.0M
$103.1M
Q3 25
$742.8M
$150.8M
Q2 25
$757.2M
$140.6M
Q1 25
$784.6M
$116.7M
Q4 24
$121.2M
Q3 24
$579.3M
$88.3M
Q2 24
$455.0M
$103.4M
Q1 24
$485.8M
$124.2M
Debt / Equity
KROS
KROS
MVIS
MVIS
Q4 25
0.35×
Q3 25
0.32×
Q2 25
0.42×
Q1 25
0.57×
Q4 24
0.68×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
KROS
KROS
MVIS
MVIS
Operating Cash FlowLast quarter
$107.5M
$-58.7M
Free Cash FlowOCF − Capex
$106.0M
$-59.4M
FCF MarginFCF / Revenue
27520.5%
-26636.3%
Capex IntensityCapex / Revenue
402.9%
304.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$239.3M
$-103.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
KROS
KROS
MVIS
MVIS
Q4 25
$107.5M
$-58.7M
Q3 25
$3.2M
$-16.5M
Q2 25
$-29.6M
$-12.7M
Q1 25
$161.2M
$-14.1M
Q4 24
$-15.1M
Q3 24
$-30.5M
$-14.1M
Q2 24
$-39.8M
$-18.6M
Q1 24
$-44.6M
$-20.8M
Free Cash Flow
KROS
KROS
MVIS
MVIS
Q4 25
$106.0M
$-59.4M
Q3 25
$3.1M
$-16.6M
Q2 25
$-30.3M
$-12.9M
Q1 25
$160.6M
$-14.2M
Q4 24
$-15.2M
Q3 24
$-30.9M
$-14.1M
Q2 24
$-40.1M
$-18.8M
Q1 24
$-45.5M
$-20.9M
FCF Margin
KROS
KROS
MVIS
MVIS
Q4 25
27520.5%
-26636.3%
Q3 25
21.9%
-6894.6%
Q2 25
-167.0%
-8346.5%
Q1 25
76.0%
-2410.4%
Q4 24
-918.7%
Q3 24
-7960.3%
-7421.1%
Q2 24
-108408.1%
-989.5%
Q1 24
-54826.5%
-2183.4%
Capex Intensity
KROS
KROS
MVIS
MVIS
Q4 25
402.9%
304.5%
Q3 25
0.9%
53.1%
Q2 25
4.0%
134.2%
Q1 25
0.3%
16.8%
Q4 24
6.2%
Q3 24
99.5%
4.7%
Q2 24
837.8%
8.7%
Q1 24
1139.8%
11.9%
Cash Conversion
KROS
KROS
MVIS
MVIS
Q4 25
Q3 25
Q2 25
Q1 25
1.09×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons